Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Fasinumab
Drug: Placebo

First Posted Date: 2015-08-06

Last Posted Date: 2016-05-12

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 72

Registration Number: NCT02516618

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Phase 2

Completed

Conditions: Osteoarthritis, Hip
Osteoarthritis, Knee

Interventions: Drug: REGN475
Drug: Placebo

First Posted Date: 2015-05-18

Last Posted Date: 2017-03-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 421

Registration Number: NCT02447276

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

Phase 2

Terminated

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: REGN2176-3
Drug: Intravitreal Aflibercept Injection (IAI)

First Posted Date: 2015-04-16

Last Posted Date: 2020-10-26

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 505

Registration Number: NCT02418754

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Dupilumab

First Posted Date: 2015-04-03

Last Posted Date: 2020-11-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 78

Registration Number: NCT02407756

A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Dupilumab

First Posted Date: 2015-03-20

Last Posted Date: 2020-03-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 422

Registration Number: NCT02395133

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancer
Advanced Malignancies

Interventions: Drug: Cemiplimab
Radiation: Hypofractionated radiotherapy
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Carboplatin
Drug: GM-CSF
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2015-03-09

Last Posted Date: 2020-01-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 398

Registration Number: NCT02383212

Locations: 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 44 locations

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Phase 2

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: Dupilumab
Drug: Placebo

First Posted Date: 2015-03-04

Last Posted Date: 2020-02-28

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 47

Registration Number: NCT02379052

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

Phase 3

Completed

Conditions: Heterozygous Familial Hypercholesterolemia

Interventions: Drug: Placebo
Drug: Alirocumab

First Posted Date: 2014-12-29

Last Posted Date: 2020-05-01

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT02326220

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Phase 3

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Suptavumab 30 mg/kg
Drug: Suptavumab 30 mg/kg- 1 Dose
Drug: Placebo Matched to Suptavumab
Drug: Suptavumab 30 mg/kg - 2 Doses

First Posted Date: 2014-12-25

Last Posted Date: 2018-11-06

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 1177

Registration Number: NCT02325791

Locations: 🇺🇸
Regeneron Investigational Site, Birmingham, Alabama, United States
🇬🇧
Regeneron Study Site, Stockton on Tees, United Kingdom

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: Odronextamab multiple dose levels

First Posted Date: 2014-11-14

Last Posted Date: 2024-11-05

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT02290951

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇫🇷
Institut Gustave Roussy, Villejuif, Île-de-France, France
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 19 locations

Home Terms & Conditions Privacy Policy